Pfizer CentreOne adds highly potent oral solid dosage forms to its contract portfolio

Global contract manufacturer Pfizer CentreOne adds highly potent OSDs to its service offering

Pfizer CentreOne, a global contract manufacturing organisation embedded within Pfizer, has grown its service portfolio to include contract manufacturing of highly potent solid oral dose medicines.

The service will be provided at the Pfizer Newbridge Ireland facility, which is now part of Pfizer CentreOne’s contract manufacturing network. The Pfizer site, near Dublin, has a long history of contract manufacturing and packaging highly potent solid oral drugs with advanced technologies.

Currently approved to supply pharmaceuticals in more than 100 markets, the site’s regulatory approvals include the FDA, EMA, Agência Nacional de Vigilância Sanitária (ANVISA) in Brazil and Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.

The Newbridge site manufactures high-potency non-cytotoxic solid oral dosage forms for human use. In addition to conventional manufacturing processes, the team has experience with compounds that require complex processes, such as modification of powder and particle properties to create novel drug formulations, or those with enhanced solubility and dissolution properties.

Pfizer CentreOne manufactures the following compound types:

  • Highly active compounds
  • Hormones
  • Immunosuppressants
  • Sensitisers
  • Controlled drugs
  • Containment technologies span Occupational Exposure Band (OEB) 1-5 (Occupational Exposure Limit down to 0.01 µg/m3). Specialised technologies include active coating, low-dosage formulations and modified/extended release.